Patents by Inventor Mark Czekaj
Mark Czekaj has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220396588Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).Type: ApplicationFiled: February 9, 2022Publication date: December 15, 2022Applicant: Genzyme CorporationInventors: John L. Kane, JR., Claude Barberis, Mark Czekaj, Paul Erdman, Barret Giese, Michael Kothe, Tieu-Binh Le, Jinyu Liu, Liang Ma, Markus Metz, Vinod Patel, Andrew Scholte, Patrick Shum, Linli Wei
-
Patent number: 11274108Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).Type: GrantFiled: July 19, 2016Date of Patent: March 15, 2022Assignee: GENZYME CORPORATIONInventors: John L. Kane, Jr., Claude Barberis, Mark Czekaj, Paul Erdman, Barret Giese, Michael Kothe, Tieu-Binh Le, Jinyu Liu, Liang Ma, Markus Metz, Vinod Patel, Andrew Scholte, Patrick Wai-Kwok Shum, Linli Wei
-
Publication number: 20190016707Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).Type: ApplicationFiled: July 19, 2016Publication date: January 17, 2019Inventors: John L. KANE, Jr., Claude Barberis, Mark Czekaj, Paul Erdman, Barret Giese, Michael Kothe, Tieu-Binh Le, Jinyu Liu, Liang Ma, Markus Metz, Vinod Patel, Andrew Scholte, Patrick Wai-Kwok Shum, Linli Wei
-
Patent number: 8828974Abstract: The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R1, P1, P2 and P3 are as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.Type: GrantFiled: April 24, 2012Date of Patent: September 9, 2014Assignee: Aventis Pharmaceuticals Inc.Inventors: Yong Mi Choi-Sledeski, Julian Levell, Gregory Bernard Poli, Mark Czekaj, Alan John Collis, Roy Vaz
-
Publication number: 20120208784Abstract: The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R1, P1, P2 and P3 are as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.Type: ApplicationFiled: April 24, 2012Publication date: August 16, 2012Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Yong Mi CHOI-SLEDESKI, Julian LEVELL, Gregory Bernard POLI, Mark CZEKAJ, Alan John COLLIS, Roy VAZ
-
Patent number: 8183231Abstract: The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R1, P1, P2 and P3 are as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.Type: GrantFiled: October 24, 2006Date of Patent: May 22, 2012Assignee: Aventis Pharmaceuticals Inc.Inventors: Yong Mi Choi-Sledeski, Julian Levell, Gregory Bernard Poli, Mark Czekaj, Alan John Collis, Roy Vaz
-
Patent number: 7482459Abstract: The present invention extends to the compound of formula I: or a prodrug, pharmaceutically acceptable salt, or solvate of said compound. Furthermore, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed to the use of a compound of formula I as an inhibitor of tryptase, comprising introducing the compound into a composition comprising tryptase. In addition, the present invention is directed to the use of a compound of formula I for treating a patient suffering from, or subject to, a physiological condition in need of amelioration of an inhibitor of tryptase comprising administering to the patient a therapeutically effective amount of the compound of claim 1 The present invention is directed also to the preparation of a compound of formula I.Type: GrantFiled: September 14, 2006Date of Patent: January 27, 2009Assignee: Aventis Pharmaceuticals Inc.Inventors: Zhongli Gao, Larry Davis, Julian Levell, Mark Czekaj, Adam W. Sledeski
-
Patent number: 7361663Abstract: This invention is directed to N-acylpyrrolidin-2-ylalkylbenzamidine derivatives which useful for inhibiting the activity of Factor Xa, by contacting said derivatives with a composition containing Factor Xa. The present invention is also directed to compositions containing said derivatives, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.Type: GrantFiled: October 16, 2003Date of Patent: April 22, 2008Assignee: Aventis Pharmaceuticals Inc.Inventors: Mark Czekaj, Scott I. Klein, Heinz W. Pauls
-
Publication number: 20070142435Abstract: The present invention extends to the compound of formula I: or a prodrug, pharmaceutically acceptable salt, or solvate of said compound. Furthermore, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed to the use of a compound of formula I as an inhibitor of tryptase, comprising introducing the compound into a composition comprising tryptase. In addition, the present invention is directed to the use of a compound of formula I for treating a patient suffering from, or subject to, a physiological condition in need of amelioration of an inhibitor of tryptase comprising administering to the patient a therapeutically effective amount of the compound of claim 1 The present invention is directed also to the preparation of a compound of formula I.Type: ApplicationFiled: September 14, 2006Publication date: June 21, 2007Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Zhongli Gao, Larry Davis, Julian Levell, Mark Czekaj, Adam Sledeski
-
Publication number: 20070060502Abstract: The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R1, P1, P2 and P3 are as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.Type: ApplicationFiled: October 24, 2006Publication date: March 15, 2007Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Yong Choi-Sledeski, Julian Levell, Gregory Poli, Mark Czekaj, Alan Collis, Roy Vaz
-
Patent number: 6977263Abstract: Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.Type: GrantFiled: April 26, 2001Date of Patent: December 20, 2005Assignee: Aventis Pharmaceuticals Inc.Inventors: Peter C. Astles, Paul R. Eastwood, Olivier Houille, Julian Levell, Heinz Pauls, Mark Czekaj, Guyan Liang, Yong Gong, James Pribish, Kent Neuenschwander
-
Publication number: 20050228018Abstract: Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.Type: ApplicationFiled: February 14, 2005Publication date: October 13, 2005Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Peter Astles, Paul Eastwood, Olivier Houille, Julian Levell, Heinz Pauls, Mark Czekaj, Guyan Liang, Yong Gong, James Pribish, Kent Neuenschwander
-
Publication number: 20040087570Abstract: This invention is directed to N-acylpyrrolidin-2-ylalkylbenzamidine derivatives which useful for inhibiting the activity of Factor Xa, by contacting said derivatives with a composition containing Factor Xa. The present invention is also directed to compositions containing said derivatives, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.Type: ApplicationFiled: October 16, 2003Publication date: May 6, 2004Applicant: AVENTIS PHARMA DEUTSCHLAND GMBHInventors: Mark Czekaj, Scott I. Klein, Heinz W. Pauls
-
Publication number: 20030187020Abstract: Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.Type: ApplicationFiled: April 26, 2001Publication date: October 2, 2003Inventors: Peter C. Astles, Paul R. Eastwood, Olivier Houille, Julian Levell, Heinz Pauls, Mark Czekaj, Guyan Liang, Yong Gong, James Pribish, Kent Neuenschwander
-
Publication number: 20030092698Abstract: This invention is directed to N-acylpyrrolidin-2-ylalkylbenzamidine derivatives which useful for inhibiting the activity of Factor Xa, by contacting said derivatives with a composition containing Factor Xa. The present invention is also directed to compositions containing said derivatives, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.Type: ApplicationFiled: May 10, 2002Publication date: May 15, 2003Inventors: Mark Czekaj, Scott I Klein, Heinz W. Pauls
-
Patent number: 5780590Abstract: The invention is directed to a non-hygroscopic stable crystalline form of the antithrombotic compound N-?N-?N-(4-piperdin-4-yl)butanoyl)-N-ethylglycyl!-(L)-aspartyl!-(L)-.beta. -cyclohexyl-alanine amide, to processes for preparing said stable crystalline form, to a pharmaceutical composition thereof, and intermediates thereof, and the invention is directed also to processes for preparing a compound of the formula ##STR1## wherein: A, B, Z, E.sup.1, E.sup.2, G, R, m, n, and p are as defined herein.Type: GrantFiled: August 21, 1996Date of Patent: July 14, 1998Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.Inventors: Scott I. Klein, Bruce F. Molino, Mark Czekaj, Charles J. Gardner
-
Patent number: 5332726Abstract: This invention relates to novel peptide and pseudopeptide derivatives and analogs of aspartic acid which are useful as inhibitors of platelet aggregation and thrombus formation in mammalian blood, to pharmaceutical compositions including such compounds, and to their use in inhibiting thrombus formation and platelet aggregation in mammals.Type: GrantFiled: March 30, 1992Date of Patent: July 26, 1994Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.Inventors: Scott I. Klein, Bruce F. Molino, Mark Czekaj, Charles Gardner, Michael R. Becker, Jeffrey M. Dener, Jeffrey C. Pelletier
-
Patent number: 5051405Abstract: Disclosed are novel peptides and pseudopeptides and pharmaceutical compositions thereof containing certain amino acids and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.Type: GrantFiled: October 10, 1989Date of Patent: September 24, 1991Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.Inventors: Scott I. Klein, Bruce F. Molino, Mark Czekaj, Charles J. Gardner
-
Patent number: 4952562Abstract: Disclosed are novel peptides and pseudopeptides and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.Type: GrantFiled: September 29, 1989Date of Patent: August 28, 1990Assignee: Rorer Pharmaceutical CorporationInventors: Scott I. Klein, Bruce F. Molino, Mark Czekaj, Charles J. Gardner, Jeffrey C. Pelletier